Boston Scientific (BSX) Expands Urology Portfolio with Valencia Deal, Analysts Emphasize Organic Growth

Boston Scientific Corporation (NYSE:BSX) is included in our list of the best stocks to buy right now.

On January 12, 2026, Boston Scientific Corporation (NYSE:BSX) shared an expansion update, announcing a definitive agreement to acquire Valencia Technologies. With this move, the company expands its Urology franchise into implantable tibial nerve stimulation (ITNS) with the FDA-approved eCoin System. The deal focuses on overactive bladder, a large and underpenetrated market, consisting of nearly 30 million U.S. adults over 40 experiencing bothersome symptoms. However, only 19% of those adults receive treatment beyond lifestyle adjustments.

eCoin features a coin-sized, minimally invasive implant, which broadens the company’s pelvic health continuum and complements existing neuromodulation and urology offerings. At the same time, it addresses patients who are refractory to or intolerant of conservative therapies. Meanwhile, clinical validation strengthens the case for Boston Scientific Corporation (NYSE:BSX), with 68% of patients in the pivotal trial recording at least a 50% reduction in urge urinary incontinence episodes. Management remains confident due to the high-growth adjacency feature of ITNS, which reinforces the company’s organic growth potential rather than a short-term earnings boost.

Separately, on January 9, 2026, Goldman Sachs shared an update, lowering its price target on Boston Scientific Corporation (NYSE:BSX) from $124 to $112, while reiterating a ‘Buy’ rating. The firm expects investor attention to refocus on organic growth in 2026, as valuations and fundamentals normalize, according to TheFly.

Boston Scientific Corporation (NYSE:BSX) is focused on developing and marketing interventional medical devices across the MedSurg and Cardiovascular segments.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 7 Best Rising Tech Stocks to Buy Now and 12 Best Multibagger Stocks to Buy Heading into 2026.

Disclosure: None.